Skip to main content

Market Overview

Sulzer To Buy Swiss-German Drug Delivery Firm Haselmeier For $118M

Sulzer To Buy Swiss-German Drug Delivery Firm Haselmeier For $118M

Sulzer AG (OTC: SULZF) announced Monday it is purchasing Swiss-German drug delivery device company Haselmeier for $118 million.

What Happened: Sulzer said the acquisition will boost its own healthcare portfolio, and Haselmeier’s expertise in precision injection molding can help it grow in the drug delivery devices market, according to a company-issued statement.

Haselmeier employs 230 people and recorded sales of $45.5 million in 2019. The company is a provider of devices such as subcutaneous self-injection pens used for reproductive health, growth disorders, osteoporosis, and diabetes.

Why It Matters: Sulzer’s applicator systems business has been severely affected due to the COVID-19 pandemic, according to the company.

The applicators division manufactures devices for adhesives in the beauty sector, car industry, and healthcare.

In June, Sulzer announced it was acquiring 25% of Tamturbo Plc, a Finnish company that makes oil-free air compressors. A month later, the company’s CEO Greg Poux-Guillaume said the company had a “very strong balance sheet” and could spend up to $1.5 billion on deals.

“We have a bit of firepower to make acquisitions,” Poux-Guillaume said at the time, as per Reuters.

Price Action: Sulzer OTC shares closed 5.11% lower at $84.45 on Friday.

Photo courtesy: Sulzer AG via Wikimedia


Related Articles (SULZF)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 HaselmeierM&A News Health Care Global General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at